Genotropin GoQuick

Replacement therapy in adults w/ pronounced growth hormone deficiency (GHD). Growth disturbance due to insufficient secretion of growth hormone & associated w/ Turner syndrome or chronic renal insufficiency in childn. Growth disturbance in short childn born small for gestational age (SGA) w/ birth wt &/or length <2 SD, who failed to show catch-up growth by ≥4 yr. Prader-Willi syndrome (PWS) for improvement of growth & body composition.

SC Adult GHD Restart w/ 0.2-0.5 mg daily. Onset GHD Start w/ 0.15-0.3 mg daily. Patient who continues growth hormone therapy after childhood GHD Restart w/ 0.2-0.5 mg daily, adjust dose gradually according to requirements. Childn GHD 0.025-0.035 mg/kg daily or 0.7-1 mg/m² daily. PWS 0.035 mg/kg daily or 1 mg/m² daily. Max: 2.7 mg daily. Turner syndrome & chronic renal insufficiency 0.045-0.05 mg/kg daily or 1.4 mg/m² daily. Short childn born SGA 0.035 mg/kg daily or 1 mg/m² daily until final height is reached. Patient >60 yr 0.1-0.2 mg daily.

Hypersensitivity. Evidence of tumour activity. Patients w/ acute critical illness suffering complications following open heart or abdominal surgery, multiple accidental traumas, acute resp failure. Childn w/ closed epiphyses.

Discontinue use if papilloedema is confirmed. Interrupt treatment if signs of upper airway obstruction occur. Not recommended to initiate treatment near onset of puberty in short childn born SGA. Not to be used in patients w/ acute critical illness suffering complications following open heart or abdominal surgery, multiple accidental trauma or acute resp failure; if overt diabetes occurs. Leukaemia; myositis; pancreatitis; Silver-Russell syndrome. Assess signs for upper airway obstruction, sleep apnoea or resp infections prior to treatment. May reduce insulin sensitivity. Closely monitor patients w/ diabetes, glucose intolerance or additional risk factors for diabetes during therapy. Monitor symptoms of intracranial HTN if treatment is restarted; thyroid function & signs of scoliosis during treatment. Measure fasting insulin & blood glucose prior to & annually in SGA childn. Assess renal function prior to initiation. May unmask previously undiagnosed central hypoadrenalism. Ab formation; relapse of GHD secondary to malignant disease treatment. Strict calorie-restricted diet & wt control in patients w/ PWS; Na-restricted diet. Concomitant use w/ oral oestrogen therapy. Discontinue treatment at renal transplantation. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Examine childn limping during treatment. Elderly >80 yr.

Arthralgia. Adults: Peripheral oedema. Paraesthesia; carpal tunnel syndrome; myalgia, musculoskeletal stiffness. Childn: Inj site reaction.

Inhibited growth-promoting effects w/ glucocorticoids. Decreased cortisone to cortisol conversion. Increased clearance of CYP450 3A4-metabolized compd eg, sex steroids, corticosteroids, anticonvulsants & ciclosporin. Concomitant use w/ oral oestrogen replacement.

Trophic Hormones & Related Synthetic Drugs

H01AC01 - somatropin ; Belongs to the class of somatropin and somatropin agonists. Used in anterior pituitary lobe hormone and analogue preparations.

B